Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease

Summary

This study is a pilot, phase II, open-label study of the angiotensin II receptor blocker, losartan, in patients with Sickle Cell Disease (SCD) 6 years or older for 12 months. The investigators will enroll 24 patients with SCD over the course of 1 year with a goal to complete all study procedures in 2 years. The short-term goal is to obtain clinical pilot data regarding the safety and efficacy of losartan in stabilizing or decreasing extracellular volume fraction (ECV) after 12 months of therapy.

Timeline

Start

2021-09-01

Primary completion

2025-10-03

Completion

2026-05-28

Drugs

Indications